阿尔茨海默病（AD）的早期诊断一直是医学领域的挑战之一。近年来，关于AD血液生物标志物的研究蓬勃发展，对促进AD早期诊断、疾病监测和早期干预有重要意义。随着新一代超敏检测技术的诞生，在血液中相继验证了AD的核心标志物、非特异性标志物及其他相关标志物。然而，血液生物标志物用于AD诊断和预测仍存在准确性和稳定性的问题。本文针对每类标志物的最新进展和优劣进行梳理分析，并提供了几种潜在策略，以克服AD血液生物标志物面临的挑战。 The early diagnosis of Alzheimer′s disease (AD) has long been a challenge in the field of medicine. In recent years, research on blood biomarkers of AD has flourished, which holds significant promise for advancing the early diagnosis, monitoring, and early intervention of AD. With the new generation of ultra-sensitive detection techniques, a series of studies have successfully validated core biomarkers, non-specific biomarkers, and other relevant biomarkers of AD in blood. However, the use of blood-based biomarkers for the diagnosis and prediction of AD still faces some challenges related to accuracy and robustness. This article compiles and analyzes the advances, strengths, and limitations of each type of biomarkers, and provides several potential strategies to address these challenges.
Prospects for the application of blood-based biomarkers in Alzheimer′s disease
The early diagnosis of Alzheimer′s disease (AD) has long been a challenge in the field of medicine. In recent years, research on blood biomarkers of AD has flourished, which holds significant promise for advancing the early diagnosis, monitoring, and early intervention of AD. With the new generation of ultra-sensitive detection techniques, a series of studies have successfully validated core biomarkers, non-specific biomarkers, and other relevant biomarkers of AD in blood. However, the use of blood-based biomarkers for the diagnosis and prediction of AD still faces some challenges related to accuracy and robustness. This article compiles and analyzes the advances, strengths, and limitations of each type of biomarkers, and provides several potential strategies to address these challenges.
万方数据
